Abstract Body

Background

Polypharmacy, defined as the use of >5 non-HIV medications, is common in older people with HIV (PWH). Polypharmacy has been evaluated mostly in cross-sectional studies which do not inform on patterns of medications use over time. This study aimed to determine polypharmacy trajectories and identify associated predictors among older PWH in the Swiss HIV Cohort Study (SHCS). 

Methods

All treated PWH aged >50 years in 2016 with longitudinal record of medications up to 2024 were included. Latent class growth models were applied to determine changes in medications use and type over time and multinomial logistic regression to identify predictors of polypharmacy trajectories.

Results

At baseline (first SHCS visit in 2016), included participants (n=3353) were 77% male, median (IQR) age: 55 (52, 61) years; 13% BMI >30 kg/m2; 20% no or mandatory school; 34% current smokers; 6.6% illicit substance users; 51% infrequent physical activity. Comorbidities prevalence was: cancer (17%), chronic kidney disease (11%), cardiovascular event (10%). Median duration of HIV infection was 27 years, 95% participants were suppressed. Antiretroviral therapy consisted mainly of unboosted INSTI regimens (55%); 69% had <5 non-HIV medications. Latent class growth models identified 4 trajectories: (1) stable non-polypharmacy (n=592, 17.6% on 3 medications, mostly vitamins/minerals, statins and ACE inhibitors), (2) rapid increasing polypharmacy (n=1560, 46.5% going from 5.5 to 8.5 medications, mostly vitamins/minerals, cardiovascular drugs, analgesics, CNS drugs), (3) slowly increasing polypharmacy (n=961, 28.7%  going from 1 to 2.5 medications mostly vitamins/minerals, statins, ACE inhibitors, and (4) rapid progression to polypharmacy (n=240, 7.2% going from 1 to 6 medications with a steep increase in cardiovascular drugs and drugs for obstructive airway diseases) (Fig. 1). HIV acquisition through injection drug use, no/mandatory school, infrequent physical activity, heavy cigarette (>20/day) smoking, and comorbidities were predictors of polypharmacy trajectory 2 relative to 1 whereas cancer and missing antiretroviral treatment >1x/month were predictors of trajectory 4 relative to 1.

Conclusions

Only 46% of SHCS PWH aged >50 years remained on <5 medications over 8 years of follow-up. Future interventions should focus on modifiable factors such as physical activity, smoking, treatment adherence also including medication review to slow/prevent the progression of polypharmacy. 

Table or Figure